安慰剂
医学
临床终点
不利影响
糖尿病
内科学
2型糖尿病
2型糖尿病
患者满意度
随机对照试验
物理疗法
外科
替代医学
内分泌学
病理
作者
Roni Weinberg Sibony,Julio Wainstein,Maya Ish‐Shalom,Tali Ganz,Aliza Rozenberg,Ilan Yanuv,Uri Eliyahu,Itamar Raz
摘要
OBJECTIVE: To examine the efficacy and safety of Curalin supplement in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Adult patients with type 2 diabetes were randomized 1:1 to receive Curalin supplement or placebo. The primary endpoint was HbA1c decrease at 1 month. The secondary endpoint was a decrease in HbA1c by more than 0.5% and 1% and a change in 7 daily blood glucose measurements. A satisfaction questionnaire was used as an exploratory endpoint. Safety variables and adverse events were assessed. RESULTS: After 1 month of intervention, HbA1c was reduced by 0.94% in the Curalin arm versus 0.4% in the placebo arm (P = 0.008). 72% of Curalin patients had decreased HbA1c levels >0.5% versus 35% in the placebo arm (P < 0.05). The Treatment Satisfaction Questionnaire indicated that Curalin arm patients reported higher overall satisfaction. CONCLUSIONS: Curalin treatment significantly reduced HbA1c over a 1-month period and was well-tolerated.
科研通智能强力驱动
Strongly Powered by AbleSci AI